Marcy Yonker
Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Migraine Disorders | 19 | 2023 | 101 | 4.170 |
Why?
| Headache | 10 | 2023 | 151 | 0.870 |
Why?
| Nasal Sprays | 1 | 2022 | 4 | 0.800 |
Why?
| Sleep Wake Disorders | 2 | 2023 | 255 | 0.750 |
Why?
| Headache Disorders, Secondary | 1 | 2018 | 4 | 0.600 |
Why?
| Pseudotumor Cerebri | 1 | 2018 | 25 | 0.580 |
Why?
| Pediatrics | 5 | 2020 | 1074 | 0.550 |
Why?
| Inpatients | 1 | 2020 | 477 | 0.490 |
Why?
| Practice Guidelines as Topic | 5 | 2020 | 1514 | 0.460 |
Why?
| Child | 23 | 2023 | 20962 | 0.450 |
Why?
| Neurology | 3 | 2020 | 103 | 0.450 |
Why?
| Headache Disorders | 3 | 2020 | 17 | 0.410 |
Why?
| Pre-Exposure Prophylaxis | 1 | 2015 | 205 | 0.410 |
Why?
| Telemedicine | 1 | 2021 | 792 | 0.390 |
Why?
| Disease Management | 1 | 2015 | 592 | 0.360 |
Why?
| Trigeminal Autonomic Cephalalgias | 1 | 2010 | 1 | 0.350 |
Why?
| Tension-Type Headache | 1 | 2010 | 8 | 0.340 |
Why?
| Calcitonin Gene-Related Peptide | 2 | 2020 | 40 | 0.320 |
Why?
| Analgesics | 3 | 2019 | 194 | 0.320 |
Why?
| Academies and Institutes | 2 | 2019 | 50 | 0.310 |
Why?
| Societies, Medical | 3 | 2020 | 759 | 0.270 |
Why?
| Adolescent | 18 | 2023 | 20451 | 0.270 |
Why?
| Pain Management | 2 | 2019 | 334 | 0.250 |
Why?
| Tryptamines | 2 | 2022 | 5 | 0.220 |
Why?
| Musculoskeletal Pain | 1 | 2023 | 34 | 0.210 |
Why?
| Serotonin 5-HT1 Receptor Agonists | 1 | 2022 | 4 | 0.200 |
Why?
| Humans | 27 | 2023 | 129847 | 0.200 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 1368 | 0.200 |
Why?
| Administration, Intranasal | 1 | 2022 | 84 | 0.200 |
Why?
| White Matter | 1 | 2023 | 135 | 0.180 |
Why?
| Double-Blind Method | 2 | 2022 | 1877 | 0.170 |
Why?
| Dopamine Antagonists | 1 | 2020 | 23 | 0.170 |
Why?
| Cross-Over Studies | 1 | 2022 | 521 | 0.170 |
Why?
| Neuromuscular Agents | 1 | 2020 | 31 | 0.160 |
Why?
| Botulinum Toxins, Type A | 1 | 2020 | 41 | 0.160 |
Why?
| Chronic Pain | 1 | 2023 | 253 | 0.160 |
Why?
| Sleep | 2 | 2023 | 689 | 0.160 |
Why?
| Transition to Adult Care | 1 | 2020 | 82 | 0.150 |
Why?
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2018 | 4 | 0.150 |
Why?
| Anticonvulsants | 3 | 2019 | 209 | 0.150 |
Why?
| Headache Disorders, Primary | 1 | 2018 | 4 | 0.150 |
Why?
| Emergency Service, Hospital | 2 | 2020 | 1920 | 0.120 |
Why?
| Histamine Antagonists | 1 | 2015 | 20 | 0.120 |
Why?
| Antidepressive Agents | 2 | 2015 | 229 | 0.120 |
Why?
| Treatment Outcome | 4 | 2022 | 10241 | 0.110 |
Why?
| Diagnosis, Differential | 1 | 2018 | 1434 | 0.110 |
Why?
| Antihypertensive Agents | 1 | 2015 | 485 | 0.090 |
Why?
| Drug Therapy, Combination | 1 | 2013 | 1042 | 0.080 |
Why?
| Research Report | 2 | 2019 | 79 | 0.080 |
Why?
| Adult | 3 | 2023 | 35634 | 0.060 |
Why?
| Female | 10 | 2023 | 68829 | 0.060 |
Why?
| Evidence-Based Medicine | 2 | 2019 | 716 | 0.060 |
Why?
| Male | 10 | 2020 | 63759 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 756 | 0.060 |
Why?
| Sumatriptan | 2 | 2019 | 8 | 0.060 |
Why?
| Acute Disease | 1 | 2006 | 980 | 0.050 |
Why?
| Retrospective Studies | 5 | 2023 | 14553 | 0.050 |
Why?
| Anxiety Disorders | 1 | 2023 | 357 | 0.040 |
Why?
| Naproxen | 1 | 2019 | 17 | 0.040 |
Why?
| Cluster Headache | 1 | 2018 | 1 | 0.040 |
Why?
| Post-Traumatic Headache | 1 | 2018 | 4 | 0.040 |
Why?
| Contraindications, Drug | 1 | 2018 | 8 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2018 | 82 | 0.040 |
Why?
| Comorbidity | 1 | 2023 | 1551 | 0.040 |
Why?
| Drug Combinations | 1 | 2019 | 331 | 0.040 |
Why?
| Body Size | 1 | 2018 | 103 | 0.040 |
Why?
| Consensus | 1 | 2020 | 622 | 0.030 |
Why?
| Pain Measurement | 2 | 2013 | 510 | 0.030 |
Why?
| Child, Preschool | 3 | 2023 | 10522 | 0.030 |
Why?
| Obesity | 1 | 2009 | 2885 | 0.030 |
Why?
| Patient Selection | 1 | 2018 | 660 | 0.030 |
Why?
| Surveys and Questionnaires | 2 | 2023 | 5437 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2018 | 2016 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 1005 | 0.030 |
Why?
| Pregnancy Complications | 1 | 2018 | 494 | 0.030 |
Why?
| United States | 2 | 2019 | 13913 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2023 | 5085 | 0.020 |
Why?
| Quality of Life | 1 | 2023 | 2695 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2020 | 4896 | 0.020 |
Why?
| Health Services Accessibility | 1 | 2018 | 903 | 0.020 |
Why?
| History, 21st Century | 1 | 2012 | 186 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2023 | 3397 | 0.020 |
Why?
| History, 20th Century | 1 | 2012 | 295 | 0.020 |
Why?
| Pregnancy | 1 | 2018 | 6423 | 0.020 |
Why?
| Ergot Alkaloids | 1 | 2005 | 1 | 0.020 |
Why?
| Migraine without Aura | 1 | 2005 | 1 | 0.020 |
Why?
| Cyproheptadine | 1 | 2005 | 7 | 0.020 |
Why?
| Serotonin Receptor Agonists | 1 | 2005 | 28 | 0.020 |
Why?
| Oxazolidinones | 1 | 2005 | 15 | 0.010 |
Why?
| Contraindications | 1 | 2005 | 90 | 0.010 |
Why?
| Reference Standards | 1 | 2005 | 176 | 0.010 |
Why?
| Biofeedback, Psychology | 1 | 2005 | 35 | 0.010 |
Why?
| Antiemetics | 1 | 2005 | 41 | 0.010 |
Why?
| Calcium Channel Blockers | 1 | 2005 | 161 | 0.010 |
Why?
| Complementary Therapies | 1 | 2005 | 87 | 0.010 |
Why?
| Young Adult | 1 | 2020 | 12467 | 0.010 |
Why?
| Triazoles | 1 | 2005 | 148 | 0.010 |
Why?
| Adrenergic beta-Antagonists | 1 | 2005 | 321 | 0.010 |
Why?
| Prevalence | 1 | 2009 | 2564 | 0.010 |
Why?
| Body Mass Index | 1 | 2009 | 2274 | 0.010 |
Why?
| Diet | 1 | 2005 | 1212 | 0.010 |
Why?
| Animals | 1 | 2018 | 35409 | 0.010 |
Why?
| Aging | 1 | 2005 | 1774 | 0.010 |
Why?
| Middle Aged | 1 | 2012 | 31177 | 0.010 |
Why?
|
|
Yonker's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|